These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Benzinga02-03 01:13

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported upbeat fourth-quarter earnings.

The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus of $10.71. The company reported sales of $3.88 billion, up 3% year over year, beating the consensus of $3.79 billion.

Regeneron expects fiscal 2026 GAAP gross margin of 79%–80%, with adjusted gross margin of 83%–84%. The company forecasts adjusted R&D expenses of $5.9–$6.1 billion in 2026, and non-GAAP SG&A expenditure between $2.5 billion and $2.65 billion.

“Regeneron performed well in 2025, with financial strength driven by our four blockbuster medicines and future growth supported by our exciting late-stage clinical portfolio,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron.

Regeneron Pharmaceuticals shares gained 2.1% to trade at $756.63 on Monday.

These analysts made changes to their price targets on Regeneron Pharmaceuticals following earnings announcement.

  • Truist Securities analyst Gregory Renza maintained Regeneron Pharmaceuticals with a Buy and lowered the price target from $820 to $818.
  • Cantor Fitzgerald analyst Carter Gould maintained the stock with an Overweight rating and raised the price target from $740 to $800.
  • Wells Fargo analyst Mohit Bansal maintained Regeneron Pharmaceuticals with an Equal-Weight rating and raised the price target from $745 to $800.
  • Morgan Stanley analyst Matthew Harrison maintained the stock with an Equal-Weight rating and raised the price target from $768 to $769.

Considering buying REGN stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment